-+ 0.00%
-+ 0.00%
-+ 0.00%

ALTIMMUNE ANNOUNCES THAT PEMVIDUTIDE ACHIEVED KEY MEASURES OF SUCCESS AT 48 WEEKS IN IMPACT PHASE 2B MASH TRIAL

路透·12/19/2025 11:30:00

登錄查看新聞詳情